CRDL
Price
$1.54
Change
+$0.15 (+10.79%)
Updated
Jul 3 closing price
Capitalization
124.33M
45 days until earnings call
SCYX
Price
$0.73
Change
+$0.01 (+1.39%)
Updated
Jul 3 closing price
Capitalization
55.88M
45 days until earnings call
Interact to see
Advertisement

CRDL vs SCYX

Header iconCRDL vs SCYX Comparison
Open Charts CRDL vs SCYXBanner chart's image
Cardiol Therapeutics
Price$1.54
Change+$0.15 (+10.79%)
Volume$368.42K
Capitalization124.33M
SCYNEXIS
Price$0.73
Change+$0.01 (+1.39%)
Volume$70.95K
Capitalization55.88M
CRDL vs SCYX Comparison Chart in %
Loading...
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDL vs. SCYX commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDL is a Hold and SCYX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (CRDL: $1.54 vs. SCYX: $0.73)
Brand notoriety: CRDL and SCYX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CRDL: 190% vs. SCYX: 58%
Market capitalization -- CRDL: $124.33M vs. SCYX: $55.88M
CRDL [@Pharmaceuticals: Other] is valued at $124.33M. SCYX’s [@Pharmaceuticals: Other] market capitalization is $55.88M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDL’s FA Score shows that 0 FA rating(s) are green whileSCYX’s FA Score has 0 green FA rating(s).

  • CRDL’s FA Score: 0 green, 5 red.
  • SCYX’s FA Score: 0 green, 5 red.
According to our system of comparison, CRDL is a better buy in the long-term than SCYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDL’s TA Score shows that 3 TA indicator(s) are bullish while SCYX’s TA Score has 4 bullish TA indicator(s).

  • CRDL’s TA Score: 3 bullish, 5 bearish.
  • SCYX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than CRDL.

Price Growth

CRDL (@Pharmaceuticals: Other) experienced а +4.76% price change this week, while SCYX (@Pharmaceuticals: Other) price change was -0.69% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.13%. For the same industry, the average monthly price growth was +3.08%, and the average quarterly price growth was +93.03%.

Reported Earning Dates

CRDL is expected to report earnings on Aug 18, 2025.

SCYX is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDL($124M) has a higher market cap than SCYX($55.9M). CRDL YTD gains are higher at: 20.313 vs. SCYX (-39.554). SCYX has higher annual earnings (EBITDA): 70.9M vs. CRDL (-30.61M). SCYX has more cash in the bank: 74.4M vs. CRDL (40.5M). CRDL has less debt than SCYX: CRDL (181K) vs SCYX (15.1M). SCYX has higher revenues than CRDL: SCYX (140M) vs CRDL (0).
CRDLSCYXCRDL / SCYX
Capitalization124M55.9M222%
EBITDA-30.61M70.9M-43%
Gain YTD20.313-39.554-51%
P/E RatioN/A1.06-
Revenue0140M-
Total Cash40.5M74.4M54%
Total Debt181K15.1M1%
FUNDAMENTALS RATINGS
CRDL vs SCYX: Fundamental Ratings
CRDL
SCYX
OUTLOOK RATING
1..100
7553
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
4492
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCYX's Valuation (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRDL (97) in the null industry. This means that SCYX’s stock grew somewhat faster than CRDL’s over the last 12 months.

SCYX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that SCYX’s stock grew similarly to CRDL’s over the last 12 months.

SCYX's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as CRDL (99) in the null industry. This means that SCYX’s stock grew similarly to CRDL’s over the last 12 months.

CRDL's Price Growth Rating (44) in the null industry is somewhat better than the same rating for SCYX (92) in the Pharmaceuticals Other industry. This means that CRDL’s stock grew somewhat faster than SCYX’s over the last 12 months.

SCYX's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that SCYX’s stock grew similarly to CRDL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDLSCYX
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BYDIY208.385.84
+2.88%
Byd Electronic International Co Ltd.
TAGOF17.75N/A
N/A
TAG Immobilien AG
HLTRF3.66N/A
N/A
HLS Therapeutics Inc.
RVCB31.00N/A
N/A
River Valley Community Bancorp
CNLTP36.00-0.15
-0.41%
Connecticut Light & Power Co. (The)

SCYX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCYX has been loosely correlated with AQST. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SCYX jumps, then AQST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+1.57%
AQST - SCYX
36%
Loosely correlated
+1.09%
CRON - SCYX
30%
Poorly correlated
+2.00%
AKAN - SCYX
30%
Poorly correlated
+5.38%
TLRY - SCYX
29%
Poorly correlated
+11.03%
ACB - SCYX
29%
Poorly correlated
+1.57%
More